Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats: Research paper

British Journal of Pharmacology

Volumn 159, Issue 7, 2010, Pages 1408-1417

  Iyer, Abishek ^a   Fenning, Andrew ^b   Lim, Junxian ^a   Le, Giang T ^a   Reid, Robert C ^a   Halili, Maria A ^a   Fairlie, David P ^a   Brown, Lindsay ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b CENTRAL QUEENSLAND UNIVERSITY   (Australia)

Author keywords

Cardiac remodelling; Fibrosis; Histone acetyltransferase; Histone deacetylase inhibitor; Hypertension; Hypertrophy

Indexed keywords

DEOXYCORTICOSTERONE ACETATE; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART MUSCLE POTENTIAL; HEART PAPILLARY MUSCLE; HEART REPOLARIZATION; HISTOPATHOLOGY; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY INFILTRATE; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SYSTOLIC HYPERTENSION; VASCULAR RING; WISTAR RAT;

ANIMALS; DESOXYCORTICOSTERONE; FIBROSIS; HEART; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; HYPERTENSION; MALE; RATS; RATS, WISTAR;

EID: 77949794821     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00637.x     Document Type: Article

References (71)

1. Adcock IM (2007). HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol 150:829 831.
2. Adcock IM, Ito K, Barnes PJ (2005). Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD 2:445 455.
3. Allan A, Fenning A, Levick S, Hoey A, Brown L (2005). Reversal of cardiac dysfunction by selective ET-A receptor antagonism. Br J Pharmacol 146:846 853.
4. Antos CL, McKinsey T, Dreitz M, Hollingsworth LM, Zhang CL, Schreiber K et al. (2003). Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem 278:28930 28937.
5. Bhavsar P, Ahmad T, Adcock IM (2008). The role of histone deacetylases in asthma and allergic diseases. J Allergy Clin Immunol 121:580 584.
6. Blanchard F, Chipoy C (2005). Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today 10:197 201.
7. Brown RD, Ambler SK, Mitchell MD, Long CS (2005a). The cardiac fibroblast: therapeutic target in myocardial remodelling and failure. Annu Rev Pharmacol Toxicol 45:657 687.
8. Brown RD, Mitchell MD, Long CS (2005b). Pro-inflammatory cytokines and cardiac extracellular matrix: regulation of fibroblast phenotype. In:Villarreal FJ (ed.). Interstitial Fibrosis in Heart Failure. Springer:New York, pp. 57 81.
9. + channels in the rat. Mol Cell Biochem 237:1 10.
10. Chan V, Hoey A, Brown L (2006). Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats. Br J Pharmacol 148:902 908.
11. Choo QY, Ho PC, Lin HS (2008). Histone deacetylase inhibitors: new hope for rheumatoid arthritis? Curr Pharma Des 14:803 820.
12. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehmann M, Walther TC et al. (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325:834 840.
13. Cruz-Gervis R, Stecenko A, Dworski R, Lane KB, Loyd JE, Pierson R et al. (2002). Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis. Respir Res 3:17 21.
14. Davidson JM (1992). Wound repair. In:Gallin JI, Goldstein RH, Snyderman R (eds). Inflammation: Basic Principles and Clinical Correlates. Raven Press, Ltd:New York, pp. 809 819.
15. Faggioni R, Jones-Carson J, Reed DA, Dinarello CA, Feingold KR, Grunfeld C et al. (2000). Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18. Proc Natl Acad Sci USA 97:2367 2372.
16. Fenning A, Harrison G, Rose'meyer R, Hoey A, Brown L (2005). L-Arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats. Am J Physiol 289:1408 1416.
17. Friedman SL (1999). Stellate cell activation in alcoholic fibrosis - an overview. Alcohol Clin Exp Res 23:904 910.
18. Gallo P, Latronico MV, Gallo P, Grimaldi S, Borgia F, Todaro M et al. (2008). Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc Res 80:416 424.
19. Glauben R, Batra A, Fedke I, Zeitz M, Lehr HA, Leoni F et al. (2006). Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 176:5015 5022.
20. Gusterson RJ, Jazrawi E, Adcock IM, Latchman DS (2003). The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity. J Biol Chem 278:6838 6847.
21. Halili MA, Andrews MR, Sweet MJ, Fairlie DP (2009). Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem 9:309 319.
22. Hinglais N, Huedes D, Nicoletti A, Manset C, Laurent M, Bariety J et al. (1994). Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab Invest 70:286 294.
23. Kagitani S, Ueno H, Hirade S, Takahashi T, Takata M, Inoue H (2004). Tranilast attenuated myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats. J Hypertens 22:1007 1015.
24. Kanzaki Y, Terasaki F, Okabe M, Hayashi T, Toko H, Shimomura H et al. (2001). Myocardial inflammatory cell infiltrates in cases of dilated cardiomyopathy as a determinant of outcome following partial left ventriculectomy. Jpn Circ J 65:797 802.
25. Kee HJ, Sohn IS, Nam KI, Park JE, Qian YR, Yin Z et al. (2006). Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113:51 59.
26. van Kerckhoven R, Kalkman EAJ, Saxena PR, Schoemaker RG (2000). Altered cardiac collagen and associated changes in diastolic function of infarcted rat hearts. Cardiovasc Res 46:316 323.
27. Kong Y, Tannous P, Lu G, Berenji K, Rothermel BA, Olson EN et al. (2006). Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 113:2579 2588.
28. Koyanagi M, Egashira K, Kubo-Inoue M, Usui M, Kitamoto S, Tomita H et al. (2000). Role of transforming growth factor-b1 in cardiovascular inflammatory changes induced by chronic inhibition of nitric oxide synthesis. Hypertension 35:86 90.
29. Kupper TS, Groves RW (1995). The IL-1 axis and cutaneous inflammation. J Invest Dermatol 105:S62 S66.
30. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K et al. (2004). Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 43:739 745.
31. Kyrylenko S, Kyrylenko O, Suuronen T, Salminen A (2003). Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases. CMLS Cell Mol Life Sci 60:1990 1997.
32. Lee TM, Lin MS, Chang NC (2007). Inhibition of histone deacetylase on ventricular remodelling in infracted rats. Am J Physiol Heart Circ Physiol 293:H968 H977.
33. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P et al. (2002). The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 99:2995 3000.
34. Leung D, Abbenante G, Fairlie DP (2000). Protease inhibitors: current status and future prospects. J Med Chem 43:305 341.
35. Levick S, Loch D, Rolfe B, Reid RC, Fairlie DP, Taylor SM et al. (2006). Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats. J Immunol 176:7000 7007.
36. Lin HS, Hu HY, Chan HY, Liew YY, Huang HP, Lepescheux L et al. (2007). Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 150:862 872.
37. Litwin SE, Katz SE, Morgan JP, Douglas PS (1994). Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infraction in the rat. Circulation 89:345 354.
38. Loch D, Hoey A, Morisseau C, Hammock BO, Brown L (2007). Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys 47:87 98.
39. Loch D, Levick S, Hoey A, Brown L (2006). Rosuvastatin attenuates hypertension-induced cardiovascular remodelling without affecting blood pressure in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol 47:396 404.
40. Lu J, McKinsey TA, Nicol RL, Olson EN (2000). Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc Natl Acad Sci USA 97:4070 4075.
41. McKinsey TA, Kass DA (2007). Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov 6:617 635.
42. McKinsey TA, Olson EN (2004). Cardiac histone acetylation - therapeutic opportunities abound. Trends Genet 20:206 213.
43. Mirkovic S, Seymour AM, Fenning A, Strachan A, Margolin SB, Taylor SM et al. (2002). Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol 135:961 968.
44. Momtaz A, Coulombe A, Richer P, Mercadier J, Coraboeuf E (1996). Action potential and plateau ionic currents in moderately and severely DOCA-salt hypertrophied rat hearts. J Mol Cell Cardiol 28:2511 2522.
45. Nakatsuji S, Yamate J, Kuwamura M, Kotani T, Sakuma S (1997). In vivo responses of macrophages and myofibroblasts in the healing following isoproterenol-induced myocardial injury in rats. Virchows Arch 430:63 69.
46. Nicoletti A, Michel J-B (1999). Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res 41:532 543.
47. Potente M, Dimmeler S (2008). Emerging roles of SIRT1 in vascular endothelial homeostasis. Cell Cycle 7:2117 2122.
48. Ratcliffe N, Hutchins J, Barry B, Hickey W (2000). Chronic myocarditis induced by T cells reactive to a single cardiac myosin peptide: persistent inflammation, cardiac dilatation, myocardial scarring and continuous myocyte apoptosis. J Autoimmun 15:359 367.
49. Richon VM (2006). Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer 95:S2 S6.
50. Rutschow S, Li J, Schultheiss HP, Pauschinger M (2006). Myocardial proteases and matrix remodelling in inflammatory heart disease. Cardiovasc Res 69:646 656.
51. Sim AS, Salonikas C, Naidoo D, Wilcken DE (2003). Improved method for plasma malondialdehyde measurement by high-performance liquid chromatography using methyl malondialdehyde as an internal standard. J Chromatogr B Analyt Technol Biomed Life Sci 785:337 344.
52. Sime PJ, Marr RA, Gauldie D, Xing Z, Hewlett BR, Graham FL et al. (1998). Transfer of tumor necrosis factor-a to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-b1 and myofibroblasts. Am J Pathol 153:825 832.
53. Stowell JC, Huot RI, Van Voast L (1995). The synthesis of N-hydroxy-N'-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells. J Med Chem 38:1411 1413.
54. Tong X, Yin L, Giardina C (2004). Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition. Biochem Biophys Res Commun 317:463 471.
55. Trivedi CM, Lu MM, Wang Q, Epstein JA (2008). Transgenic overexpression of HDAC3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy. J Biol Chem 283:26484 26489.
56. Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T et al. (2007). Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3b activity. Nat Med 13:324 331.
57. Verdin E, Dequiedt F, Kasler HG (2003). Class II histone deacetylases: versatile regulators. Trends Genet 19:286 293.
58. Villarreal FJ, Griffin M, Omens J, Dillmann W, Nguyen J, Covell J (2003). Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation 108:1487 1492.
59. Vyalov S, Desmouliere A, Gabbiani G (1993). GM-CSF-induced granulation tissue formation: relationships between macrophage and myofibroblast accumulation. Virchows Arch B Cell Pathol Incl Mol Pathol 63:231 239.
60. + channel function by tumor necrosis factor-a: role of reactive oxygen species as a mediator. J Biol Chem 279:13289 13292.
61. Weber KT (1996). Wound healing following myocardial infarction. Clin Cardiol 19:447 455.
62. Weber KT (1997). Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. Semin Nephrol 17:467 491.
63. Weber KT, Brilla CG, Janicki JS (1993). Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 27:341 348.
64. Wen Y, Gu J, Peng X, Zang G, Nadler J (2003). Overexpression of 12-lipoxygenase and cardiac fibroblast hypertrophy. Trends Cardiovasc Med 13:129 136.
65. Westermann D, Rutschow S, Van Linthout S, Linderer A, Bücker-Gärtner C, Sobirey M et al. (2006). Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia 49:2507 2513.
66. Willems IE, Havenith MG, De Mey JG, Daemen MJ (1994). The alpha-smooth muscle actin-positive cells in healing human myocardial scars. Am J Pathol 145:868 875.
67. Wise LD, Spence S, Saldutti LP, Kerr JS (2008). Assessment of female and male fertility in Sprague-Dawley rats administered vorinostat, a histone deacetylase inhibitor. Birth Defects Res B Dev Reprod Toxicol 83:19 26.
68. Woolf P, Lu S, Cornford-Nairn R, Watson M, Xiao X-H, Holroyd S et al. (2006). Alterations in dihydropyridine receptors in dystrophin-deficient cardiac muscle. Am J Physiol 290:H2439 H2445.
69. Wu R, Laplante MA, de Champlain J (2004). Prevention of angiotensin II-induced hypertension, cardiovascular hypertrophy and oxidative stress by acetylsalicylic acid in rats. J Hypertens 22:793 801.
70. Zalewski A, Shi Y (1997). Vascular myofibroblasts. Lessons from coronary repair and remodelling. Arterioscler Thromb Vasc Biol 17:417 422.
71. Zhang C, McKinsey T, Chang S, Antos CL, Hill JA, Olson EN (2002). Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110:479 488.